Evolving First-Line HER2+ Metastatic Breast Cancer with Drs. Sonya Reid & Shruti Singh

Community Health Media · Sep 1, 2026 · 29m

For more than a decade, THP—established by the landmark CLEOPATRA trial— defined the first-line standard for HER2-positive metastatic breast cancer. Now, DESTINY-Breast09 is changing the conversation.

In this CHM Conversation, Dr. Sonya Reid and Dr. Shruti Singh discuss the evolving first-line treatment landscape and how trastuzumab deruxtecan (T-DXd) plus pertuzumab is reshaping clinical decision-making for patients with HER2-positive metastatic breast cancer.

They explore which patients may benefit most from a T-DXd-based approach, how prior T-DXd exposure in early-stage disease could…